HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting

This item is licensed under: Creative Commons Attribution 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1002/jgh3.12209


Title: Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting
Authors: Sho, Takuya Browse this author
Suda, Goki Browse this author →KAKEN DB
Ogawa, Koji Browse this author →KAKEN DB
Kimura, Megumi Browse this author
Shimazaki, Tomoe Browse this author
Maehara, Osamu Browse this author
Shigesawa, Taku Browse this author
Suzuki, Kazuharu Browse this author
Nakamura, Akihisa Browse this author
Ohara, Masatsugu Browse this author
Umemura, Machiko Browse this author
Kawagishi, Naoki Browse this author →KAKEN DB
Natsuizaka, Mitsuteru Browse this author →KAKEN DB
Nakai, Masato Browse this author
Morikawa, Kenichi Browse this author
Furuya, Ken Browse this author
Baba, Masaru Browse this author
Yamamoto, Yoshiya Browse this author
Kobayashi, Tomoe Browse this author
Meguro, Takashi Browse this author
Saga, Akiyoshi Browse this author
Miyagishima, Takuto Browse this author
Yokoo, Hideki Browse this author →KAKEN DB
Kamiyama, Toshiya Browse this author →KAKEN DB
Taketomi, Akinobu Browse this author →KAKEN DB
Sakamoto, Naoya Browse this author →KAKEN DB
Keywords: early response
lenvatinib
real world
REFLECT
Issue Date: Feb-2020
Publisher: John Wiley & Sons
Journal Title: JGH open
Volume: 4
Issue: 1
Start Page: 54
End Page: 60
Publisher DOI: 10.1002/jgh3.12209
Abstract: Background and AimLenvatinib has been recently approved as a first-line systematic therapy for patients with advanced hepatocellular carcinoma (HCC) based on the results of the phase 3 clinical trial REFLECT. This trial excluded patients with a history of systemic chemotherapy, bile duct invasion, and Child-Pugh grade B. We aimed to investigate the efficacy and safety of lenvatinib for these patients and in the real-world setting. MethodsAmong patients who were administered lenvatinib for advanced HCC between April and October 2018 in Hokkaido University Hospital and related hospitals, we evaluated those who were followed for more than 2 months and whose treatment response was evaluated via dynamic computed tomography at baseline and 2 months after treatment initiation. Meanwhile, patients were excluded if they had decompensated liver cirrhosis, were followed up less than 2 months, or were not evaluated at 2 months. Patients were also stratified according to compliance with the REFLECT inclusion criteria for further analysis. ResultsA total of 41 patients were included; more than 50% did not meet the REFLECT inclusion criteria. In total, 5 (12.2%), 20 (48.8%), 12 (29.3%), and 4 (9.3%) showed complete response, partial response, stable disease, and progressive disease, respectively. The objective response rate was 61.2%. The objective response rate and disease control rate were similar between patients who did and did not meet the REFLECT inclusion criteria. Moreover, the safety profile was also similar between the two patient groups. ConclusionLenvatinib showed high early response rate and tolerability in patients with advanced HCC. Favorable outcomes were similarly observed in patients who did not meet the REFLECT inclusion criteria.
Rights: https://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/77028
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University